RxDoctor Payments Data

Jeffrey Reyer, DO

Family Medicine · Greensburg, PANPI 1801996756

Payments from drug & device makers

$1,622in general payments, 2019–2025

Across 143 payments — averaging $11.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$768
  • Lilly USA, LLC$190
  • AstraZeneca$165
  • Pfizer$98
  • Boehringer Ingelheim$75
  • Merck$73
  • plus $253 from 7 others

What the payments were for

  • Food & beverage$1,622100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,622 in reported general payments places this provider in the 75th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$59,378
Medicare patients
144
Services billed
599

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide98$129,280
FarxigaDapagliflozin Propanediol101$122,691
JardianceEmpagliflozin73$92,059
EliquisApixaban104$85,491
RybelsusSemaglutide34$45,804
MounjaroTirzepatide40$44,357
TrulicityDulaglutide33$34,836
JanuviaSitagliptin Phosphate15$25,073
XareltoRivaroxaban17$21,118
ProliaDenosumab12$19,814
WegovySemaglutide15$19,654
Humalog Kwikpen U-100Insulin Lispro36$12,122
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$7,120
Fluticasone-SalmeterolFluticasone Propion/Salmeterol37$6,633
Rosuvastatin Calcium464$6,598

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Wegovy$768$194,738147 claims
AstraZenecaFarxiga$165$122,691101 claims
Boehringer IngelheimJardiance$75$92,05973 claims
PfizerEliquis, Paxlovid$98$86,920128 claims
Lilly USA, LLCMounjaro, Trulicity$190$79,19373 claims
MerckJanuvia$73$25,07315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Greensburg

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →